ATRA treatment increases the levels of thrombomodulin, reduces the production of tissue factor and cancer procoagulant by leukemic cells, and down-regulates the expression of annexin II cell surface receptors in APL malignant cells, resulting in a notable improvement in the coagulopathy associated with this malignant disorder [18]. The gene discussed is CD177; the disease is cancer.